Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study

Lung Cancer

Volumn 96, Issue , 2016, Pages 113-119

  Weiss, Elisabeth ^a   Ford, John C ^a,b   Olsen, Kathryn M ^c,d   Karki, Kishor ^a   Saraiya, Siddharth ^a   Groves, Robert ^c   Hugo, Geoffrey D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Diffusion weighted MRI; Non small cell lung cancer; Radiotherapy; Response assessment

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; LYMPH NODE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NECROSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PILOT STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE; CANCER STAGING; DIAGNOSTIC IMAGING; DRUG EFFECTS; LUNG TUMOR; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TUMOR VOLUME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; TUMOR BURDEN;

EID: 84962809943     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.04.001     Document Type: Article

References (32)

1. Bains L.J., Zweifel M., Thoeny H.C. Therapy response with diffusion MRI: an update. Cancer Imaging 2012, 12:395-402.
2. Heusch P., Buchbender C., Köhler J., Nensa F., Beiderwellen K., Kühl H., Lanzman R.S., Wittsack H.J., Gomez B., Gauler T., Schuler M., Forsting M., Bockisch A., Antoch G., Heusner T.A. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Fortschr. Röntgenstr. 2013, 185:1056-1062.
3. Kosucu P., Tekinbas C., Erol M., Sari A., Kavgaci H., Oztuna F., Ersöz S. Mediastinal lymph nodes: assessment with diffusion weighted MR imaging. J. Magn. Reson. Imaging 2009, 30:292-297.
4. Mori T., Nomori H., Ikeda K., Kawanaka K., Shiraishi S., Katahira K., Yamashita Y. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J. Thorac. Oncol. 2008, 3:358-364.
5. Nakayama J., Miyasaka K., Omatsu T., Onodera Y., Terae S., Matsuno Y., Cho Y., Hida Y., Kaga K., Shirato H. Metastases in mediastinal and hilar lymph nodes in patients with non small cell lung cancer: quantitative assessment with diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient. J. Comput. Assist. Tomogr. 2010, 34:1-8.
6. Nomori H., Mori T., Ikeda K., Kawanaka K., Shiraishi S., Katahira K., Yamashita Y. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J. Thorac. Cardiovasc. Surg. 2008, 135:816-822.
7. Razek A.A.F.A., Fathy A., Gawad T.A. Correlation of apparent diffusion coefficient value with prognostic parameters of lung cancer. J. Comput. Assist. Tomogr. 2011, 35:248-252.
8. Usuda K., Sagawa M., Motono N., Ueno M., Tanaka M., Machida Y., Matoba M., Kuginuki Y., Taniguchi M., Ueda Y., Sakuma T. Advantages of diffusion-weighted imaging over positron emission tomography-computed tomography in assessment of hilar and mediastinal lymph node in lung cancer. Ann. Surg. Oncol. 2013, 20:1676-1683.
9. Uto T., Takehara Y., Nakamura Y., Naito T., Hashimoto D., Inui N., Suda T., Nakamura H., Chida K. Higher sensitivity and specificity for diffusion weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 2009, 252:247-254.
10. Chang Q., Wu N., Ouyang H., Huang Y. Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. Clin. Imaging 2012, 36:98-103.
11. Iizukaa Y., Matsuoa Y., Umeokab S., Nakamoto Y., Ueki N., Mizowaki T., Togashi K., Hiraoka M. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and18F-fDG PET. Eur. J. Radiol. 2014, 83:2087-2092.
12. Ohno Y., Koyama H., Yoshikawa T., Matsumoto K., Aoyama N., Onishi Y., Sugimura K. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. Am. J. Roentgenol. 2012, 198:75-82.
13. Okuma T., Matsuoka T., Yamamoto A., Hamamoto S., Nakamura K., Inoue Y. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumors by diffusion-weighted MRI: a pilot study. Br. J. Radiol. 2009, 82:989-994.
14. Tsuchida T., Morikawa M., Demura Y., Umeda Y., Okazawa H., Kimura H. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. J. Magn. Reson. Imaging 2013, 38:80-88.
15. Yabuuchi H., Hatakenaka M., Takayama K., Matsuo Y., Sunami S., Kamitani T., Jinnouchi M., Sakai S., Nakanishi Y., Honda H. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology 2011, 261:598-604.
16. Baysal T., Mutlu D.Y., Yologlu S. Diffusion-weighted magnetic resonance imaging in differentiation of postobstructive consolidation from central lung carcinoma. Magn. Reson. Imaging 2009, 27:1447-1454.
17. Chen L., Zhang J., Chen Y., Wang W., Zhou X., Yan X., Wang J. Relationship between apparent diffusion coefficient and tumor cellularity in lung cancer. PLoS One 2014, 9:e99865.
18. Matoba M., Tonami H., Kondou T., Yokota H., Higashi K., Toga H., Sakuma T. Lung carcinoma: diffusion-weighted MR imaging-preliminary evaluation with apparent diffusion coefficient. Radiology 2007, 243:570-577.
19. Padhani A.R., Koh D.-M. Diffusion MR imaging for monitoring of treatment response. Magn. Reson. Imaging Clin. N. Am. 2011, 19:181-209.
20. Yang R.-M., Li L., Wei X.-H., Guo Y.M., Huang Y.H., Lai L., Chen A.M., Liu G.S., Xiong W.F., Luo L.P., Jiang X.Q. Differentiation of central lung cancer from atelectasis: comparison of diffusion-weighted MRI with PET/CT. PLoS One 2013, 8:e60279.
21. Galbán S., Brisset J.C., Rehemtulla A., Chenevert T.L., Ross B.D., Galbán C.J. Diffusion-weighted MRI for assessment of early cancer treatment response. Curr. Pharm. Biotechnol. 2010, 11:701-708.
22. Bral S., De Ridder M., Duchateau M., Gevaert T., Engels B., Schallier D., Storme G. Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:1338-1342.
23. Brink C., Bernchou U., Bertelsen A., Hansen O., Schytte T., Bentzen S.M. Cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. Int. J. Radiat. Oncol. Biol. Phys. 2014, 89:916-923.
24. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1. 1). Eur. J. Cancer 2009, 45:228-247.
25. Regier M., Derlin T., Schwarz D., Laqmani A., Henes F.O., Groth M., Buhk J.H., Kooijman H., Adam G. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?. Eur. J. Radiol. 2012, 81:2913-2918.
26. Le Bihan D., Breton E., Lallemand D., Aubin M.L., Vignaud J., Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988, 168:497-505.
27. Karki K., Hugo G.D., Ford J.C., Olsen K.M., Saraiya S., Groves R., Weiss E. Estimation of the optimal b-value sets for obtaining apparent diffusion coefficient free from perfusion in non-small cell lung cancer. Phys. Med. Biol. 2015, 60:7877-7891.
28. Bernardin L., Douglas N.H.M., Collins D.J., Giles S.L., O'Flynn E.A., Orton M., DeSouza N.M. Diffusion-weighted magnetic resonance imaging for assessment of lung lesions: repeatability of the apparent diffusion coefficient measurement. Eur. J. Radiol. 2014, 24:502-511.
29. Gong N.-J., Wong C.-S., Chu Y.-C., Guo H., Huang B., Chan Q. Increasing the accuracy of volume and ADC delineation for heterogeneous tumor on diffusion-weighted MRI: correlation with PET/CT. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87:407-413.
30. Hamstra D.A., Galban C.J., Meyer C.R., Johnson T.D., Sundgren P.C., Tsien C., Lawrence T.S., Junck L., Ross D.J., Rehemtulla A., Ross B.D., Chenevert T.L. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J. Clin. Oncol. 2008, 26:3387-3394.
31. Rose C.J., Mills S.J., O'Connor J.P., Buonaccorsi G.A., Roberts C., Watson Y., Cheung S., Zhao S., Whitcher B., Jackson A., Parker G.J. Quantifying spatial heterogeneity in dynamic contrast enhanced MRI parameter maps. Magn. Reson. Med. 2009, 62:488-499.
32. Chen X., Qin L., Pan D., Huang Y., Yan L., Wang G., Liu Y., Liang C., Liu Z. Liver diffusion-weighted MR imaging: reproducibility comparison of ADC measurements obtained with multiple breath-hold, free-breathing, respiratory-triggered, and navigator-triggered techniques. Radiology 2014, 271:113-125.